|Slideshows|April 12, 2021

The Mighty Blueberry

Studies suggest blueberries may have the power to treat depression...

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

ByAmit Etkin, MD, PhD

June 9th 2026

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ByLeighann Forbes, PhD

June 8th 2026

Antidepressant Use in Pregnancy & Autism/ADHD in Children: Most Comprehensive Study to Date Finds No Clear Link

ByLeah Kuntz

May 14th 2026

Treatment of Inflammation to Relieve Depression and Anhedonia

ByKenneth J. Bender, PharmD, MA

May 12th 2026

Podcast: Psychedelics for Depression and Other Mental Health Conditions. The Way Forward With Guy Goodwin, MD

ByJoseph F. Goldberg, MD,Guy Goodwin, MD

May 8th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Mighty Blueberry

Related Content

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

Antidepressant Use in Pregnancy & Autism/ADHD in Children: Most Comprehensive Study to Date Finds No Clear Link

Treatment of Inflammation to Relieve Depression and Anhedonia

Podcast: Psychedelics for Depression and Other Mental Health Conditions. The Way Forward With Guy Goodwin, MD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Monoamines: A Full House

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap

Dose Lithium Once a Day at Night: An Update

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD